KI8751
CAS No. 228559-41-9
KI8751( Ki8751 | Ki-8751 | Ki 8751 )
Catalog No. M13630 CAS No. 228559-41-9
Ki8751 is a potent and selective inhibitor of VEGFR2 with IC50 of 0.9 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 28 | In Stock |
|
| 5MG | 43 | In Stock |
|
| 10MG | 70 | In Stock |
|
| 25MG | 142 | In Stock |
|
| 50MG | 279 | In Stock |
|
| 100MG | 489 | In Stock |
|
| 200MG | 635 | In Stock |
|
| 500MG | 972 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameKI8751
-
NoteResearch use only, not for human use.
-
Brief DescriptionKi8751 is a potent and selective inhibitor of VEGFR2 with IC50 of 0.9 nM.
-
DescriptionKi8751 is a potent and selective inhibitor of VEGFR2 with IC50 of 0.9 nM, >40-fold selective for VEGFR2 than c-Kit, PDGFRα and FGFR-2, little activity to EGFR, HGFR and InsR.(In Vitro):Ki8751 inhibits VEGFR-2 phosphorylation at an IC50 value of 0.90 nM, and also inhibits the PDGFR family members such as PDGFRR and c-Kit at 67 nM and 40 nM, respectively. However, Ki8751 does not have any inhibitory activity against other kinases such as EGFR, HGFR, InsulinR and others even at 10000 nM. Ki8751 suppresses the growth of the VEGF-stimulated human umbilical vein endothelial cell (HUVEC) on a nanomolar level.(In Vivo):Ki8751 shows significant antitumor activity against five human tumor xenografts such as GL07 (glioma), St-4 (stomach carcinoma), LC6 (lung carcinoma), DLD-1 (colon carcinoma) and A375 (melanoma) in nude mice and also shows complete tumor growth inhibition with the LC-6 xenograft in nude rats following oral administration once a day for 14 days at 5 mg/kg without any body weight loss.
-
In VitroKi8751 inhibits VEGFR-2 phosphorylation at an IC50 value of 0.90 nM, and also inhibits the PDGFR family members such as PDGFRR and c-Kit at 67 nM and 40 nM, respectively. However, Ki8751 does not have any inhibitory activity against other kinases such as EGFR, HGFR, InsulinR and others even at 10000 nM. Ki8751 suppresses the growth of the VEGF-stimulated human umbilical vein endothelial cell (HUVEC) on a nanomolar level.
-
In VivoKi8751 shows significant antitumor activity against five human tumor xenografts such as GL07 (glioma), St-4 (stomach carcinoma), LC6 (lung carcinoma), DLD-1 (colon carcinoma) and A375 (melanoma) in nude mice and also shows complete tumor growth inhibition with the LC-6 xenograft in nude rats following oral administration once a day for 14 days at 5 mg/kg without any body weight loss.
-
SynonymsKi8751 | Ki-8751 | Ki 8751
-
PathwayAngiogenesis
-
Targetc-Kit
-
Recptorc-Kit| EGFR| FGFR2| PDGFRα| VEGFR2
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number228559-41-9
-
Formula Weight469.41
-
Molecular FormulaC24H18F3N3O4
-
Purity>98% (HPLC)
-
SolubilityDMSO: 47 mg/mL (100.12 mM)
-
SMILESO=C(NC1=CC=C(OC2=CC=NC3=CC(OC)=C(OC)C=C23)C=C1F)NC4=CC=C(F)C=C4F
-
Chemical Name1-(2,4-difluorophenyl)-3-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-2-fluorophenyl)urea
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Kubo K, et al. J Med Chem, 2005, 48(5), 1359-1366.
molnova catalog
related products
-
CS-2660
CS-2660, a highly selective, orally available, well tolerated VEGFR2 inhibitor with IC50 of 40 nM, inhibits closely related tyrosine kinases such as Ret and Kit with IC50 of 180 nM and 500 nM.
-
KBP-7018 hydrochlori...
A novel potent, multikinase inhibitor with IC50 of 10, 7.6 and 25 nM for c-Kit, RET and PDGFRβ, respectively.
-
AMG-25
AMG-25 is a novel selective and potent c-Kit inhibitor.
Cart
sales@molnova.com